Abstract
Cryoglobulinemic vasculitis (CV) is a small and medium-size vasculitis characterized by the occurrence in the serum of reversibly precipitating proteins, named cryoglobulins and immunochemically formed by an IgM component (monoclonal or polyclonal) with rheumatoid factor activity and a polyclonal IgG component (mixed cryoglobulins). CV is almost invariably associated to chronic HCV infection. In addition to the typical purpura/asthenia/arthralgia syndrome, the pleomorphic clinical picture often includes membrano-proliferative glomerulonephritis and motor-sensory axonopathy. Hemorrhagic alveolitis, gastrointestinal vasculitis, heart failure and hyperviscosity syndrome are less frequently observed. The amount of cryoprecipitate, named cryocrit, is not strictly related to the clinical severity of CV and to the viral load. Rheumatoid factor activity and low levels of the complement C4 (sometimes also of C3 and CH50) are unfailing serological abnormalities. The pathogenetic mechanism of CV is still incompletely defined, but it can be essentially ascribed to the formation of HCV particles/IgG/IgM macromolecular complexes that are good acceptors of C1q and can therefore bind to the C1q receptors on the endothelial cells. This would eventually trigger the onset of a leukocytoclastic vasculitis. Although with wide geographic variations, CV can progress to non-Hodgkin lymphoma (NHL), possibly through an impaired regulatory control of B-cell growth. In Italy, approximately 5 % of B-cell NHLs seem to be HCV-related. Therapy of CV should be adapted to each patient’s condition. Low daily doses of corticosteroids can mitigate arthralgias and possibly prevent flares, but their long-term administration should be avoided for their inevitable side effects. Pulsed intravenous infusions of corticosteroids can prevent organ damage in the course of severe vasculitis flares. High rates of sustained virologic responses can be achieved with the use of the new interferon-free, all-oral direct acting antiviral agents. In patients with refractory/relapsing or with severely active CV, characterized by B-cell clonal expansion, a B-cell depleting therapy with rituximab often results in a satisfactory control of clinical features, although the viral load may sometimes transiently increase. Low-grade and indolent HCV-related NHLs have been found to undergo complete or partial remission following anti-HCV therapy. Finally, double filtration plasmapheresis can contribute to the improvement and possibly healing of chronic ulcers on the legs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dammacco F, Sansonno D, Piccoli C, Tucci FA, Racanelli V (2001) The cryoglobulins: an overview. Eur J Clin Invest 31:628–638
Agnello V (1997) The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 19:111–129
Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N (1966) Cryoglobulinemia – a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 40:837–856
Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E et al (1991) Antibodies against hepatitis C virus in mixed cryoglobulinemia patients. Infection 19:417–420
Agnello V, Chung RT, Kaplan LM (1992) A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 327:1490–1495
Dammacco F, Sansonno D (1992) Antibodies to hepatitis C virus in essential mixed cryoglobulinaemia. Clin Exp Immunol 87:352–356
Misiani R, Bellavita P, Fenili D, Borelli G, Marchesi D, Massazza M et al (1992) Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 117:573–577
Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A et al (2015) Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol 7:327–343
Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D (2015) Cryoglobulinemia vasculitis. Am J Med 128:950–955
Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F, Sansonno D (2013) Impact of cryoglobulinemic syndrome on the outcome of chronic hepatitis C virus infection: a 15-year prospective study. Medicine (Baltimore), 26 August 2013 [Epub ahead of print]
Monaco S, Ferrari S, Gajofatto A, Zanusso G, Mariotto S (2012) HCV-related nervous system disorders. Clin Dev Immunol 2012;2012:236148
Monaco S, Mariotto S, Ferrari S, Calabrese M, Zanusso G, Gajofatto A et al (2015) Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: advances in 2015. World J Gastroenterol 21:11974–11983
Dammacco F, Sansonno D (2013) Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 369:1035–1045
Gorevic PD (2012) Rheumatoid factor, complement, and mixed cryoglobulinemia. Clin Dev Immunol 2012;2012:439018
Gorevic PD (2012) Mixed cryoglobulinemia (MC) cross-reactive idiotypes (CRI): structural and clinical significance. In: Dammacco F (ed) HCV infection and cryoglobulinemia. Springer, Milan, pp 99–105
Ferri C, Antonelli A, Sebastiani M, Colaci M, Zignego AL (2012) The expanding spectrum of clinical features in HCV-related mixed cryoglobulinemia. In: Dammacco F (ed) HCV infection and cryoglobulinemia. Springer, Milan, pp 155–162
Carlson JA, Cavaliere LF, Grant-Kels JM (2006) Cutaneous vasculitis: diagnosis and management. Clin Dermatol 24:414–429
Sansonno D, Cornacchiulo V, Iacobelli AR, Di Stefano R, Lospalluti M, Dammacco F (1995) Localization of hepatitis C virus antigens in liver and skin tissues of chronic hepatitis C virus-infected patients with mixed cryoglobulinemia. Hepatology 21:305–312
Agnello V, Abel G (1997) Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia. Arthritis Rheum 40:2007–2015
Fabrizi F, Plaisier E, Saadoun D, Martin P, Messa P, Cacoub P (2013) Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis 61:623–637
Sansonno D, Gesualdo L, Manno C, Schena FP, Dammacco F (1997) Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 25:1237–1244
Mariotto S, Ferrari S, Monaco S (2014) HCV-related central and peripheral nervous system demyelinating disorders. Inflamm Allergy Drug Targets 13:299–304
Vallat JM, Magy L, Richard L, Piaser M, Sindou P, Calvo J et al (2008) Intranervous immunoglobulin deposits: an underestimated mechanism of neuropathy. Muscle Nerve 38:904–911
Sansonno D, Dammacco F (2005) Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 5:227–236
Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG et al (2003) Hepatitis C virus and B-cell non-hodgkin lymphomas: an italian multicenter case–control study. Blood 102:996–999
Zignego AL, Gragnani L, Piluso A, Sebastiani M, Giuggioli D, Fallahi P et al (2015) Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. Expert Rev Clin Immunol 11:15–31
de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM et al (2008) Hepatitis C and non-hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol 6:451–458
Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S et al (2011) Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 10:444–454
Cacoub P, Terrier B, Saadoun D (2014) Hepatitis C virus-induced vasculitis: therapeutic options. Ann Rheum Dis 73:24–30
Gragnani L, Fognani E, Piluso A, Boldrini B, Urraro T, Fabbrizzi A et al (2015) MaSVE study group. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology 61:1145–1153
Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR et al (1994) Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 84:3336–3343
Feld JJ, Jacobson IM, HĂ©zode C, Asselah T, Ruane PJ, Gruener N et al (2015) Sofosbuvir and velpatasvir for HCV genotypes 1, 2, 4, 5, and 6 infection. N Engl J Med 373:2599. doi:10.1056/NEJMoa1512610
Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S et al (2015) Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373:2608. doi:10.1056/NEJMoa1512612
Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM et al (2015) Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373:2618. doi:10.1056/NEJMoa1512614
Racanelli V, Sansonno D, Piccoli C, D'Amore FP, Tucci FA, Dammacco F (2001) Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients. J Immunol 167:21–29
Vallat L, Benhamou Y, Gutierrez M, Ghillani P, Hercher C, Thibault V et al (2004) Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 50:3668–3678
Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K et al (2011) Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 117:5425–5437
Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818–3826
Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G et al (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827–3834
Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V et al (2010) Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 116:343–353
Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V et al (2002) Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347:89–94
Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P et al (2014) Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol 25:1404–1410
Carrier P, Jaccard A, Jacques J, Tabouret T, Debette-Gratien M, Abraham J, Mesturoux L, Marquet P, Alain S, Sautereau D, Essig M, Loustaud-Ratti V (2015) HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int 35:2222–2227
Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, Sibon D, Thieblemont C, Dupuis J, Terrier B, Feray C, Tilly H, Pol S, Leblond V, Settegrana C,Rabiega P, Barthe Y, Hendel-Chavez H, Nguyen-Khac F, Merle-Béral H, Berger F, Molina T, Charlotte F, Carrat F, Davi F, Hermine O, Besson C; ANRS HC-13 Lympho-C Study Group (2015) Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol 90: 197–203
Tasleem S, Sood GK (2015) Hepatitis C associated B-cell Non-hodgkin lymphoma: clinical features and the role of antiviral therapy. J Clin Transl Hepatol 3:134–139
Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J et al (2010) Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 116:5119–5125
Marignani M, Mangone M, Cox MC, Angeletti S, Veggia B, Ferrari A et al (2011) HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Dig Liver Dis 43:139–142
Paydas S (2015) Hepatitis C, virus and lymphoma. Crit Rev Oncol Hematol 93:246–256
Ramunni A, Lauletta G, Brescia P, Saliani MT, Montrone M, Chironna M, Sansonno D, Dammacco F, Coratelli P (2008) Double-filtration plasmapheresis in the treatment of leg ulcers in cryoglobulinemia. J Clin Apher 23:118–122
Acknowledgments
This work was supported by grants from the University of Bari and the Italian Association for Cancer Research (AIRC), Milano.
Potential Conflict of Interest
Nothing to report.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Dammacco, F., Russi, S., Sansonno, D. (2016). HCV-Related Cryoglobulinemic Vasculitis: An Overview. In: Dammacco, F., Ribatti, D., Vacca, A. (eds) Systemic Vasculitides: Current Status and Perspectives. Springer, Cham. https://doi.org/10.1007/978-3-319-40136-2_29
Download citation
DOI: https://doi.org/10.1007/978-3-319-40136-2_29
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-40134-8
Online ISBN: 978-3-319-40136-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)